阿米奥达龙使用与白内障风险之间的关联:基于人群的活跃对比研究
Sheng-Yin To1,2,3, Hsin-Ting Lin4,5, Chun-Cheng Liao6,7,8
1Graduate Institute of Life Sciences, National Defense Medical Center, Taipei 114, Taiwan.
Postgraduate medical journal
|March 20, 2024
概括
与普罗帕芬相比,阿米奥达龙的使用不会增加白内障的风险. 这项研究没有发现任何显著的关联,这表明阿米奥达龙对白内障的发展是安全的.
科学领域:
- 心脏病学 心脏病学
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿米奥达龙的眼部副作用令人担忧.
- 阿米奥达龙与白内障形成之间的联系仍然不清楚.
研究的目的:
- 调查阿米奥达龙使用与白内障风险之间的关联.
- 在分析中控制潜在的混因素.
主要方法:
- 基于人口的队列研究,使用台湾国家医疗保险数据 (2001-2013).
- 对比了12,055名阿米奥达龙使用者与普罗法使用者 (成年人>40岁).
- 使用逆概率治疗权重 (IPTW) 和考克斯回归进行分析.
主要成果:
- 在主要分析中,没有发现阿米奥达龙和白内障之间的显著因果关系 (aHR 0.994,IPTW-aHR 0.977).
- 在心力衰竭患者 (IPTW-aHR 0.708) 和2年随访期间 (IPTW-aHR 0.889) 观察到白内障风险显著降低.
结论:
- 阿米奥达龙是一种常见的抗失常药,与普罗帕芬相比,它不会增加白内障的风险.
- 需要进一步的研究来了解潜在的机制和临床影响.
相关概念视频
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
992
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
992
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
832
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
832
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Pharmacovigilance
830
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
830
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
743
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
743


